Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
about
Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction?PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLDThe Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells.Effect of sildenafil on neuropathic pain and hemodynamics in ratsPhosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.Reversal of diabetic vasculopathy in a rat model of type 1 diabetes by opiorphin-related peptidesVardenafil protects isolated rat hearts at reperfusion dependent on GC and PKGRole of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.The use of phosphodiesterase 5 inhibitors with concomitant medications.Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy.Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.Functional muscle ischemia in Duchenne and Becker muscular dystrophy.Intravenous sildenafil in right ventricular dysfunction with pulmonary hypertension following a heart transplant.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model.Effect of periodic sildenafil dosage on intraocular pressure in patients with erectile dysfunctionInduction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow.RAF-isotype switching: from B to C through PDE.Crosstalk between G-protein and Ca2+ pathways switches intracellular cAMP levels.Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer.
P2860
Q27025843-646AB4C9-9D90-4DEC-8794-EB1078EE8B88Q30474822-BBE3E683-5542-4998-9A4E-5E371D997F75Q33559599-C963A856-637F-4D62-AB8A-023CAD750806Q33565270-7EF1B7B9-687F-4EE7-AC1D-B04279F61E54Q34357737-4AA79EA9-B86C-46FE-A855-F0E4BED191A5Q35395573-31612F7E-CB66-4D33-9959-CCC194B61281Q36735813-1922380C-95F8-432C-A43D-D6B4C18BC5ABQ37129351-70ABE344-D681-4545-97D9-FC02924B1BAFQ37321940-3D6733E6-79AE-4B25-8E7B-0E18FE8DAF7DQ37604365-0E79656B-14CB-4541-A04D-CAA714201270Q38130262-8DD9D007-B9E5-41E2-AB85-F63CAD20E9CCQ38175976-2090C27A-CECA-4617-8574-85C00BF3D223Q38725627-249DB573-A017-448A-A5E9-F135EBF3A01EQ38815890-054BEAF0-8F3B-4946-AAF2-568440778E67Q38927027-4BFE638B-C401-4B25-999A-5C172A965E42Q42373085-112FC643-2280-45B5-BE1C-C1B81B70683BQ42946648-0190FCCD-173B-423B-8F02-74D622D239C2Q43103116-09DDE736-6AD6-4F60-8AF7-B8FD63BD01C9Q46198932-B4D0A2C5-F7D5-4634-8334-D3D2B8E08696Q48282386-90D65EFD-1CBF-49AF-9FD8-41D636227C17
P2860
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Type 5 phosphodiesterase inhib ...... on and cardiovascular disease.
@ast
Type 5 phosphodiesterase inhib ...... on and cardiovascular disease.
@en
type
label
Type 5 phosphodiesterase inhib ...... on and cardiovascular disease.
@ast
Type 5 phosphodiesterase inhib ...... on and cardiovascular disease.
@en
prefLabel
Type 5 phosphodiesterase inhib ...... on and cardiovascular disease.
@ast
Type 5 phosphodiesterase inhib ...... on and cardiovascular disease.
@en
P2093
P1433
P1476
Type 5 phosphodiesterase inhib ...... on and cardiovascular disease.
@en
P2093
Gautham Ravipati
John A McClung
Stephen J Peterson
Wilbert S Aronow
William H Frishman
P356
10.1097/01.CRD.0000233904.77128.49
P577
2007-03-01T00:00:00Z